Media ReleasesSUDA Pharmaceuticals

View All SUDA Pharmaceuticals News


SUDA Pharmaceuticals - Anagrelide Project Update


SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, advises that SUDA has contracted the services of MedPharm, who will perform formulation development work to assist in stabilising and optimising the oral spray formulation for anagrelide.

MedPharm is a world-leading Contract Development and Manufacturing Organisation (CDMO) that focus on topical and transdermal product design and development services.

For more information, download the attached PDF.

Download this document